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Abstract 
 
Patients with end-stage liver disease are often hyponatremic due to multiple physiologic 
processes associated with hepatic failure. For severely hyponatremic patients 
undergoing liver transplantation, intraoperative sodium management of serum sodium 
concentration ([Na]s) is challenging. Serum sodium concentration [Na]s tends to 
increase during transplantation by the administration of fluids with higher sodium 
concentration than the patient’s [Na]s. An overly rapid sodium correction increase in 
[Na]s (> 1 mEq L-1 h-1) is difficult to avoid and increases the risk of serious perioperative 
complications. encephalopathy, prolonged endotracheal intubation and osmotic 
demyelination syndrome. We report the successful use of intravenous desmopressin to 
reverse an overly rapidly rising rise in [Na]s during living donor liver transplantation. 
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Introduction 
 
Chronic hyponatremia is common in patients with end-stage liver disease (ESLD). 
Management of hyponatremia around the time of liver transplantation is challenging 
because of the pathophysiology of ESLD and fluid shifts during surgery. Low serum 
sodium concentration ([Na]s) inevitably increases during transplantation, and overly 
rapid correction is associated with longer postoperative endotracheal intubation, 
hospital length of stay, and neurologic complications including osmotic demyelination 
syndrome (ODS).1-4 This report describes the successful intraoperative use of 
desmopressin as rescue therapy to reverse the an overly rapid rise in [Na]s correction of 
hyponatremia in a preoperatively hyponatremic patient undergoing living donor liver 
transplantation (LDLT).  
 
 
Written HIPAA authorization was obtained from the patient for publication of this case 
report. This report discusses the off-label use of desmopressin acetate for re-lowering 
the [Na]s of a hyponatremic patient. Desmopressin is approved by the U.S. Food and 
Drug Administration for treatment of hemophilia A, von Willebrand’s disease (Type I), 
central diabetes insipidus, and nocturnal polyuria. 
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Case Description  
 
A 57-year-old, 79 kg female with decompensated cirrhosis and hepatocellular 
carcinoma secondary to hepatitis C was scheduled for LDLT. Her cirrhosis was 
complicated by chronic hyponatremia, volume overload, hepatic encephalopathy, and 
thrombocytopenia. The patient was taking furosemide and spironolactone for ascites 
management, and these medications likely contributed to her hyponatremia. The [Na]s 
had fluctuated between 125-130 mEq/L for six weeks prior to transplantation, eventually 
reaching 124 mEq/L the day of surgery. The preoperative laboratory results included 
serum creatinine concentration 1.26 mg/dL, total bilirubin 3.8 mg/dL, international 
normalized ratio (INR) 1.8, hemoglobin 10.5 g/dL, and platelet count 46 x 109/L. The 
Model for End-Stage Liver Disease (MELD)-Na score was 28, which is associated with 
a three-month mortality of about 20%. 
 
The patient was brought to the operating room for right lobe LDLT. Several measures 
were implemented early in the operative course to limit the rate of increase in [Na]s 
(Figure). A hypotonic crystalloid infusion was administered throughout the operation. 
Half-normal (0.45%) saline was selected over 5% dextrose because of a history of 
diabetes. The serum glucose concentration ranged from 88-181 mg/dL and was 
maintained with an IV insulin infusion. Volume loss from drainage of ascites was 
replaced with 25 g of 25% albumin, rather than 5% albumin, to minimize sodium 
administration. Intravenous furosemide and chlorothiazide were administered to 
promote natriuresis. Autologous cell salvage and transfusion of packed red blood cells 
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(RBCs) were performed with a Continuous AutoTransfusion System (C.A.T.S.®, 
Fresenius Kabi, Bad Homburg, Germany) using the high-quality wash setting, which 
brings the [Na] of the RBC supernatant to approximately that of normal saline (Table 1). 
No sodium bicarbonate was administered. Despite these measures, [Na]s increased 
rapidly following transfusion of fresh frozen plasma (FFP) and platelets (Figure) 
required to treat coagulopathy and severe thrombocytopenia (nadir fibrinogen 
concentration 102 mg/dL, peak INR 2.2, and intraoperative nadir platelet count 21 x 
109/L). [Na]s increased to 132 mEq/L by the sixth hour of surgery, representing a rate of 
change greater than 1 mEq L-1 h-1.  
 
Considering the [Na]s trajectory and the need for ongoing transfusions, we administered 
desmopressin 24 µg (0.3 µg/kg) IV over 20 minutes in an attempt to reverse the rapid 
increase in [Na]s. Subsequently, [Na]s decreased linearly over the next four hours to 128 
mEq/L (Figure). The overall increase in [Na]s was less than 0.5 mEq L-1 h-1 for the 
remainder of the perioperative period despite ongoing FFP and platelet transfusions.  
  
The surgery lasted 7.3 hours. Fluid balance consisted of administration of 2.7 L 
crystalloid solution, 6 units packed RBCs, 12 units FFP, and 8 units of platelets 
obtained by apheresis, 3 L urine output, and 2.5 L estimated blood loss. The 
endotracheal tube was removed on postoperative day one. [Na]s remained between 
130-134 mEq/L for the first four days after surgery and plateaued at 136 mEq/L at 
hospital discharge on postoperative day nine. The patient recovered without neurologic 
complication. 
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Discussion 
 
Severe hyponatremia ([Na]s < 125 mEq/L) has a prevalence of 5.7% among cirrhotic 
patients.5 Hyponatremia is caused by the release of physiologic mediators in response 
to systemic vasodilation during ESLD. Vasodilation activates the renin-angiotensin-
aldosterone system, the sympathetic nervous system, and release of antidiuretic 
hormone from the posterior pituitary. These changes act to restore circulating blood 
volume and perfusion pressure through systemic vasoconstriction, sodium reabsorption, 
and decreased free water excretion.6,7 This impaired capacity to excrete urinary free 
water leads to a dilutional hypervolemic hyponatremia. 
 
Hyponatremia in ESLD is associated with severe ascites, hepatorenal syndrome, 
spontaneous bacterial peritonitis, encephalopathy, and overall worse outcomes.5 During 
chronic hyponatremia brain cells adapt to lower plasma osmolarity by reducing the 
amount of solute in their cytoplasm. This adaptation decreases the osmotic pressure 
gradient and minimizes cellular swelling and cerebral edema.1,8 With rapid correction of 
hyponatremia, normalization of serum osmolarity may outpace the cell’s ability to 
recapture the lost osmolytes8 and lead to astrocyte cell death, breakdown of the myelin 
sheath, disruption of the blood-brain barrier,9 and possibly ODS. Patients with advanced 
liver disease are at high risk for ODS8 which imparts a grim prognosis.2 The overall 
incidence of ODS in liver transplantation is reported as 0.5%-1%,2 but the risk is higher 
in patients with preoperative hyponatremia, higher MELD-Na scores, and greater 
swings in perioperative [Na]s.10 
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For hospitalized liver failure patients with asymptomatic hyponatremia, the 
recommended serum sodium correction rate is 4-6 mEq/L in 24 hours and should not 
exceed 8 mEq/L in 24 hours.8 In reality, it is very difficult to avoid such rates during liver 
transplantation, particularly in patients with severe hyponatremia. Liver transplant 
surgery requires considerable intravascular volume repletion, and almost all intravenous 
fluids and blood products contain relevant amounts of sodium (Table 1).11 Furthermore, 
allograft function helps restore sodium homeostasis, thereby promoting rapid [Na]s 
correction. If transplantation is anticipated in hours to days, slow preoperative correction 
of severe hyponatremia can be attempted through fluid restriction and diuretic 
withdrawal.7 However, this technique may lead to uncomfortable thirst or worsening 
ascites for the patient and careful monitoring is required. Preoperative correction was 
not an option for our patient who was admitted from home just prior to transplantation. 
 
A combined strategy of limiting isotonic intravenous fluids, avoiding sodium bicarbonate, 
administering hypotonic crystalloid solution, and administering loop diuretics has been 
proposed to slow the intraoperative increase in [Na]s during liver transplantation.12 We 
recommend implementing some or all of these interventions in patients with severe 
hyponatremia (Table 2), and frequent intraoperative [Na]s measurements (at least once 
per hour).  Prothrombin complex concentrate and fibrinogen concentrate were not 
administered in our case, but may help reduce the sodium load when substituted for 
large volumes of FFP. However, if all of these strategies fail, another treatment to 
reverse a rapid intraoperative increase in [Na]s is required.  
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Desmopressin is a synthetic vasopressin analogue that activates V2 receptors in the 
renal collecting tubules.13 It may slow or reverse a rapid increase in [Na]s by increasing 
free water reabsorption. Desmopressin is an effective and well-tolerated treatment for 
overcorrection of [Na]s in hypovolemic hyponatremic patients who may develop a water 
diuresis after intravascular volume repletion with saline.8 Restoration of hyponatremia 
by desmopressin appears to be safe and may improve acute neurologic symptoms 
concerning for impending osmotic demyelination syndrome ODS.14 
 
To our knowledge, the intraoperative use of desmopressin to reverse an overly rapid 
rise in [Na]s correction of hyponatremia in a preoperatively hyponatremic patient has not 
to our knowledge, previously been described in the literature reported. In our case, 
desmopressin helped to counteract the rapid increase in [Na]s from caused by 
administration of large volumes of sodium-rich FFP and platelets during liver 
transplantation (Figure).  The optimal dose and timing of administration of desmopressin 
for this purpose has not been established. Previous work has recommended Doses of 
2-4 µg IV every 8 hours have been recommended for the treatment of hypovolemic 
hyponatremic patients with for [Na]s correction > 1 mEq L-1 h-1.7,14 However, a robust 
antidiuretic effect is seen with the higher dose of 0.3 µg/kg when administered for 
platelet dysfunction or active bleeding. This dosage is well-tolerated by adult patients.13 
Since we were facing ongoing coagulopathy and thrombocytopenia in addition to [Na]s 
overcorrection, the higher dose of desmopressin was administered in the hope of dual 
benefit. Following this single dose, [Na]s decreased to a safe level despite ongoing FFP 
and platelet transfusions.  
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Desmopressin is generally safe, but can reduce [Na]s to a greater degree than desired, 
which in severe cases can lead to cerebral edema, seizures, and death.15 Pediatric 
patients may be at increased risk.15 After a dose of Following desmopressin 
administration, frequent [Na]s measurements must be performed frequently monitored 
and trended into the postoperative period in order to identify avoid over- or 
undercorrection. 
 
In conclusion, intraoperative management of chronically hyponatremia in hyponatremic 
patients undergoing liver transplantation is a common and challenging. problem. [Na]s 
often rises at dangerous rates and no established treatment protocol currently exists. 
Although further studies are necessary, our experience suggests that desmopressin 
may be a safe and effective intervention to reverse a rapid increase in [Na]s during liver 
transplantation, thereby possibly reducing the risk of associated postoperative 
complications including osmotic demyelination syndrome. ODS. We recommend that 
desmopressin be considered during liver transplantation when the absolute increase in 
[Na]s exceeds 8 mEq/L or there is a sustained increase exceeding 1 mEq L-1 h-1, 
especially when additional transfusions are expected and other interventions have failed 
(Table 2). 
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Table 
 
Table 1. Sodium content of intravenous fluids commonly administered during liver 
transplantation. 
 
Type of Fluid Sodium Content (mEq/L) 
Crystalloids Dextrose 5% water 0 
0.45% (half-normal) saline 77 
0.9% (normal) saline 154 
Lactated Ringer’s 130 
Plasma-Lyte 140 
Colloids 5% albumin 130-160 
25% albumin 130-160 
Blood products  Platelets 172 
Fresh frozen plasma 170 
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Table 2: Interventions to limit the increase in serum sodium concentration in patients 
with severe chronic hyponatremia during liver transplantation. 
 
Minimize sodium administration 
     Administer hypotonic crystalloid infusion (dextrose 5% water or 0.45% saline) 
     Avoid sodium bicarbonate (8.4% solution has a sodium content of 1000 mEq/L) 
     Substitute prothrombin complex concentrate and fibrinogen concentrate for FFP 
Maximize sodium excretion 
     Administer loop and thiazide diuretics  
Increase free water reabsorption 
     Administer desmopressin 
FFP; fresh frozen plasma. 
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Figure Legend: 
 
Figure. Blue line and filled circles: perioperative course of serum sodium concentration 
([Na]s). Shaded gray area: operating room time. Dashed lines: modeled trajectory of 
increase in [Na]s of 1 mEq L-1 h-1 (red line) and 0.5 mEq L-1 h-1 (black line) from case 
start. Yellow and green circles: times of transfusion of fresh frozen plasma (FFP) and 
platelets. Cyan and magenta diamonds: times of administration of 500 mL of half-
normal saline (1/2NS) and 50 mL of 25% albumin (Alb). Blue arrow: time of 
desmopressin administration. X: time of tracheal extubation. 
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